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BACKGROUND & AIMS: Noninvasive methods have been
evaluated for the assessment of liver ﬁbrosis and steatosis in
patients with nonalcoholic fatty liver disease (NAFLD). We
compared the ability of transient elastography (TE) with the M-
probe, and magnetic resonance elastography (MRE) to assess
liver ﬁbrosis. Findings from magnetic resonance imaging
(MRI)based proton density fat fraction (PDFF) measurements
were compared with those from TE-based controlled attenua-
tion parameter (CAP) measurements to assess steatosis.
METHODS: We performed a cross-sectional study of 142 pa-
tients with NAFLD (identiﬁed by liver biopsy; mean body mass
index, 28.1 kg/m2) in Japan from July 2013 through April 2015.
Our study also included 10 comparable subjects without NAFLD
(controls). All study subjects were evaluated by TE (including
CAP measurements), MRI using the MRE and PDFF techniques.
RESULTS: TE identiﬁed patients with ﬁbrosis stage 2 with an
area under the receiver operating characteristic (AUROC) curve
value of 0.82 (95% conﬁdence interval [CI]: 0.740.89), whereas
MRE identiﬁed these patients with an AUROC curve value of 0.91
(95% CI: 0.860.96; P ¼ .001). TE-based CAP measurements
identiﬁed patients with hepatic steatosis grade 2 with an
AUROC curve value of 0.73 (95% CI: 0.640.81) and PDFF
methods identiﬁed them with an AUROC curve value of 0.90
(95% CI: 0.820.97; P < .001). Measurement of serum keratin
18 fragments or alanine aminotransferase did not add value to
TE or MRI for identifying nonalcoholic steatohepatitis. CON-
CLUSIONS: MRE and PDFF methods have higher diagnostic
performance in noninvasive detection of liver ﬁbrosis and
steatosis in patients with NAFLD than TE and CAP methods.
MRI-based noninvasive assessment of liver ﬁbrosis and stea-
tosis is a potential alternative to liver biopsy in clinical practice.
UMIN Clinical Trials Registry No. UMIN000012757.
Keywords: Diagnosis; Classiﬁcation; Alanine Transaminase;
Overweight.onalcoholic fatty liver disease (NAFLD) is an impor-
1,2Ntant cause of chronic liver injury inmany countries.
A recent study has shown that the risk of developing NAFLD
is 411 times higher in patients with metabolic syndrome as
compared with healthy individuals.3 NAFLD ranges from
benign nonalcoholic fatty liver (NAFL) to nonalcoholic stea-
tohepatitis (NASH). This latter condition includes progressive
ﬁbrosis4 and hepatocellular carcinoma.5,6 Liver biopsy is
recommended as the gold standard method for the diagnosis
and grading of steatosis, hepatic inﬂammation, and hepato-
cellular ballooning, and the staging of liver ﬁbrosis in patients
with NASH.7 However, because of increased cost, possible
risk, and health care resource use, an invasive liver biopsy is a
poorly suited diagnostic test for such a prevalent condition.8
In addition, the histologic lesions of NASH are unevenly
distributed throughout the liver parenchyma, therefore, liver
biopsy sampling error can result in substantial stratiﬁcation
and staging inaccuracies.9
Assessment of the severity of liver ﬁbrosis and steatosis
is important in the evaluation of the stage of NAFLD.
Transient elastography (TE; Fibroscan, EchoSens, Paris,
France) is a useful technique that allows rapid and nonin-
vasive measurement of mean tissue stiffness.10 We have
reported that liver stiffness measurement (LSM) obtained
using TE was useful for estimation of severity of liver
ﬁbrosis in NAFLD.11,12 Meta-analysis of TE has also shown
that LSM accurately reﬂected liver ﬁbrosis.13 In addition,
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parameter (CAP), which is based on the properties of
ultrasonic signals acquired using TE.14 Recent clinical
studies using the TE system have demonstrated an increase
in the CAP with severe fat accumulation and liver stiffness
with advanced ﬁbrosis in NAFLD patients.15–17 Body mass
index (BMI) >28 kg/m2 has been identiﬁed as an inde-
pendent risk factor for failure to measure liver elastography
and fat accumulation.18 Therefore, TE has the limitation that
sometimes LSM and CAP cannot be measured in morbidly
obese patients with NAFLD.
Magnetic resonance elastography (MRE) is a magnetic
resonance imaging (MRI)-based method for quantitatively
imaging tissue stiffness, and is available from several man-
ufacturers of MRI scanners as an option that includes spe-
cial hardware and software. Quantitative stiffness images
(elastograms) of the liver can be obtained rapidly duringTable 1.Clinical, Serologic, and Histologic Characteristics of C
Characteristic Contro
n 10
Age, y, mean ± SD 52.1 ± 1
Sex, male/female 6/4
BMI, kg/m2, mean ± SD 21.9 ± 0
Platelets, /104 mL, mean ± SD 22.8 ± 4
AST, IU/L, mean ± SD 23.4 ± 8
ALT, IU/L, mean ± SD 24.3 ± 7
g-GTP, IU/L, mean ± SD 39.0 ± 6
C-reactive protein, mg/L, mean ± SD 0.06 ± 0
Creatinine, mg/dL, mean ± SD 0.63 ± 0
Fasting blood glucose, mg/dL, mean ± SD 92.1 ± 1
Fasting insulin, mU/mL, mean ± SD 7.47 ± 2
HbA1c, mean ± SD 5.62 ± 0
Diabetes mellitus, % 0
Hypertension, % 0
Dyslipidemia, % 0
Length of specimens, mm, mean ± SD
Number of portal areas, mean ± SD
Steatosis grade, n
5%33%
33%66%
>66%
Lobular inﬂammation (n)
None
<2 foci per 200 ﬁeld
24 foci per 200 ﬁeld
>4 foci per 200 ﬁeld
Liver cell ballooning (n)
None
Few balloon cells
Many balloon cells
NAFL/NASH, n
NAS, n
1/2/3/4/5/6/7
Fibrosis stage, n
None
Perisinusoidal or periportal
Perisinusoidal and portal/periportal
Bridging ﬁbrosis
Cirrhosis
ALT, alanine transaminase; AST, aspartate aminotransferase; gbreath-hold acquisitions, and can therefore be readily
included in conventional liver MRI protocols.19 Multiple
studies have also shown that MRE-based LSM provides an
accurate biomarker for detecting the presence of ﬁbrosis in
patients with chronic liver dysfunction.20–24 Indeed, MRE
has been reported to be a useful method for the diagnosis of
liver ﬁbrosis in patients with NAFLD, even in the early
stages.25–27 Proton density fat fraction (PDFF) measurement
is an MRI-based method for quantitatively assessing hepatic
steatosis and is available from several manufacturers of MRI
scanners as an option. MRI-determined PDFF correlates
with histologically determined steatosis grade in patients
with NAFLD.28,29 Although MRI can be performed even in
morbidly obese patients with NAFLD, where it is sometimes
difﬁcult to perform TE, there are no reports that have
directly compared the diagnostic accuracy of MRI and TE for
assessing both ﬁbrosis and steatosis in patients with NAFLD.ontrol Subjects and Patients With NAFLD
l NAFLD P value
142
5.1 57.5 ± 14.6 .362
81/61 .321
.69 28.1 ± 4.63 <.001
.31 20.9 ± 7.69 .442
.12 44.5 ± 26.3 <.001
.31 56.2 ± 42.6 <.001
.73 80.0 ± 87.7 .297
.03 0.17 ± 0.09 .003
.32 0.77 ± 0.42 .672
6.3 110.3 ± 28.2 .001
.98 19.2 ± 20.8 .001
.61 6.43 ± 1.10 .002
71 (50.0)
45 (31.7)
94 (66.2)
21.3 ± 1.94
14.3 ± 4.42
59
59
24
6
78
52
6
32
96
14
34/108
6/15/32/51/30/5/3
14
51
32
34
11
-GTP, gamma-glutamyl transferase.
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Figure 1. Relationship be-
tween LSM obtained using
MRE or TE and liver
ﬁbrosis stage in control
subjects and patients with
NAFLD. (A) A steady
stepwise increase in LSM
for both MRE and TE was
observed with increasing
severity of liver ﬁbrosis
(Kruskal-Wallis test;
P < .001). (B) The diag-
nostic accuracy of the
LSM obtained using MRE
or TE for liver ﬁbrosis
stage in patients with
NAFLD. The AUROC curve
is shown regarding the
performance of the LSM in
distinguishing liver ﬁbrosis
stage 0 from stages 14,
01 from 24, 0–2 from
34, and 03 from 4.
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systems, TE and MRE for the staging of liver ﬁbrosis, and to
compare TE-based CAP and MRI-based PDFF methods for
grading hepatic steatosis in the same individuals.Methods
Subject Characteristics
This cross-sectional study included patients evaluated at
Yokohama City University Hospital, Yokohama, Japan. The
cohort consisted of 142 patients, all of whom had liver bio-
psydiagnosed NAFLD, including 34 with NAFL and 108 with
NASH, and they were enrolled between July 2013 and April
2015. The time interval between clinical scoring systems, MRI,
TE, and liver biopsy was <6 months. Patients with a history of
excessive alcohol consumption (weekly consumption >140 g
for men or >70 g for women), other liver diseases, such as
chronic hepatitis, drug use associated with fatty liver, weightTable 2.Diagnostic Accuracy of MRE and TE in Detecting Each
Fibrosis
stage
MRE (n ¼ 142)
Cut-off
level, kPa AUROC 95% CI Se Sp PPV NP
1 2.5 0.80 0.710.89 75.0 85.7 99.0 84.
2 3.4 0.89 0.850.94 87.3 85.0 88.4 83.
3 4.8 0.89 0.830.95 74.5 86.9 74.5 81.
4 6.7 0.97 0.941.00 90.9 94.5 58.8 99.
NPV, negative predictive value; PPV, positive predictive value;reduction, renal diseases, or thyroid disorders were excluded.
The control group consisted of 10 subjects with a mean age and
sex ratio comparable with those of the NAFL and NASH groups
and all had normal liver enzyme levels; ultrasonography and
liver biopsy showed no evidence of a fatty liver. The study
protocol was reviewed and approved by the ethics review
committee of each institution, and all subjects provided written
informed consent before examination. The study protocol
conformed to the ethical guidelines of the Declaration of Hel-
sinki and was conducted with the approval of the Ethics
Committee of Yokohama City University Hospital. This trial is
registered with the UMIN Clinical Trials Registry as No.
UMIN000012757.Histopathologic and Immunohistochemical
Evaluations
Liver biopsy samples were obtained from all patients with
NAFLD using a 16-gauge needle biopsy kit according to aStage of Liver Fibrosis
TE (n ¼ 127)
V
Cut-off
level, kPa AUROC 95% CI Se Sp PPV NPV
6 7.0 0.78 0.700.87 61.7 100.0 100.0 86.6
6 11.0 0.82 0.740.89 65.2 88.7 88.2 66.2
0 11.4 0.88 0.790.97 85.7 83.8 75.0 91.9
2 14.0 0.92 0.860.98 100.0 75.9 73.0 100.0
Se, sensitivity; Sp, speciﬁcity.
Table 3.Diagnostic Accuracy of MRE, TE, and Scoring Systems in Detecting Each Stage of Liver Fibrosis
Modality
Fibrosis stage (n ¼ 127)
Stage 0 vs stage 14 Stage 01 vs stage 24 Stage 02 vs stage 34 Stage 03 vs stage 4
AUROC 95% CI
P
value
vs MRE
P value AUROC 95% CI
P
value
vs MRE
P value AUROC 95% CI
P
value
vs MRE
P value AUROC 95% CI
P
value
vs MRE
P value
MRE 0.83 0.720.93 .003 0.91 0.860.96 <.001 0.89 0.830.94 <.001 0.97 0.941.00 <.001
TE 0.78 0.700.87 .003 .466 0.82 0.740.89 <.001 .001a 0.88 0.790.97 <.001 .426 0.92 0.860.98 <.001 .049a
FIB-4 indexb 0.80 0.680.93 .003 .712 0.83 0.760.90 <.001 .023a 0.86 0.790.92 <.001 .384 0.88 0.820.95 .001 .036a
NFSc 0.82 0.700.93 .002 .870 0.82 0.740.89 <.001 .006a 0.860 0.800.92 <.001 .435 0.92 0.860.97 <.001 .132
APRId 0.61 0.350.86 .443 .118 0.54 0.440.64 .402 <.001a 0.61 0.510.71 .130 <.001a 0.65 0.460.83 .128 .002a
AARe 0.62 0.420.82 .155 .089 0.77 0.690.85 <.001 .003a 0.72 0.630.81 .002 .001a 0.71 0.560.86 .143 <.001a
BARDf 0.65 0.430.87 .164 .172 0.73 0.650.82 .002 <.001a 0.693 0.660.73 .002 .002a 0.68 0.570.80 .019 <.001a
aMRE was signiﬁcantly superior to the modality.
bFIB-4 index ¼ age (y)  aspartate aminotransferase (AST) (IU/L)/[platelets (109/L)  alanine transaminase (ALT)1/2 (IU/L)].
cNFS ¼ 1.675 þ 0.037  age (y) þ 0.094  BMI (kg/m2) þ 1.13  impaired fasting glycemia/diabetes (yes ¼ 1, no ¼ 0) þ 0.99  AST/ALT ratio  0.013  platelet
(109/L)  0.66  albumin (g/dL).
dAPRI ¼ [(AST/upper limit of normal AST)  100]/platelets (109/L).
eAAR ¼ AST/ALT ratio.
fBARD score ¼ AAR 0.8 (2 points), BMI 28 (1 point), presence of diabetes (1 point).
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LIVERstandard protocol; 2 specimens were obtained from each
patient to acquire a sample of sufﬁcient size for analysis and
to reduce histologic errors. An adequate liver biopsy sample
was deﬁned as being >20 mm in length and/or with >10
portal tracts. Livers were assessed histologically by 2 pa-
thologists. Macrovesicular steatosis affecting at least 5% of
hepatocytes was observed in all patients with NAFLD;
these patients were classiﬁed as having (NASH) or not
having steatohepatitis (NAFL). Patients with steatosis,
inﬂammation, ballooned hepatocytes, and pericellular/peri-
sinusoidal ﬁbrosis were classiﬁed as having NASH.30 Stea-
tosis, lobular inﬂammation, and ballooned hepatocytes
were classiﬁed as shown in the Supplementary Material.
Fibrosis severity was scored as described previously.31
Patients with NASH-associated cirrhosis were deﬁned
clinicopathologically.32Magnetic Resonance Elastography
All of the included patients underwent hepatic MRE exam-
inations performed using 3.0-T imagers (GE Healthcare, Mil-
waukee, WI) located at several different clinical sites on our
campus; a 2-dimensional MRE protocol was used, similar to one
described previously in the literature between December
2013 and April 2015.23 MRE methods are detailed in the
Supplementary Material. Interpretation of MRE images was
performed by abdominal radiologists in the Department of
Radiology following protocols established in the department, as
described previously.25 The LSM obtained at the time of
examination was entered into the database and extracted for
the present study.Assessment of Steatosis Using Magnetic
Resonance ImagingBased Proton
Density Fat Fraction
PDFF was measured using a modiﬁed Dixon method with
advanced processing (IDEAL IQ, GE Healthcare).3335 PDFF
methods are described in the Supplementary Material. Close to
the regions of interest (ROIs) drawn for the LSM, new ROIs
were drawn on the in-phase and out-of phase images for PDFF
measurements. The PDFF was calculated as reported pre-
viously.3335 LSM and PDFF were analyzed by one author who
was blinded to the liver histology results.Transient Elastography
The LSM was obtained using a TE (M-probe, Fibroscan:
EchoSens, Paris, France) by one operator. Details of the tech-
nique and the examination procedure have been described in
previous reports.10,36 Additionally, TE methods are detailed in
the Supplementary Material. At the same time, hepatic steatosis
was assessed using the CAP value provided by the device, only
when the LSM was valid for the same signals, ensuring that the
liver ultrasonic attenuation was obtained simultaneously from
the same volume of liver parenchyma as the LSM.Scoring Systems
Based on a review of the literature, the following scores
were calculated for each patient: Fibrosis-4 index37; NAFLD
ﬁbrosis score38; aspartate aminotransferase to platelet ratio
index,39 aspartate aminotransferase to alanine transaminase
ratio, and the BARD score.40Figure 2. Relationship be-
tween steatosis assess-
ments obtained using
MRI-based PDFF and TE-
based CAP methods and
pathology-based steatosis
grade in control subjects
and patients with NAFLD.
(A) A steady stepwise in-
crease in both PDFF and
CAP was observed with
increasing grade of stea-
tosis (Kruskal-Wallis test;
P < .001). (B) The diag-
nostic accuracy of the
PDFF and CAP methods in
assessing steatosis in
control subjects and pa-
tients with NAFLD. The
AUROC curve is shown for
the performance of the
PDFF or CAP in dis-
tinguishing steatosis grade
0 (controls) from grades
13, 01 from 23, and
02 from 3.
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Continuous variables were summarized as means and SDs
and categorical variables as frequencies and percentages. All
statistical analyses were performed using SPSS software
(version 12, SPSS Inc., Chicago, IL). The t test and analysis of
variance with Scheffé multiple testing correction were used for
univariate comparisons between groups. Because many of the
variables were not normally distributed, the Kruskal-Wallis test
was used for comparisons of >2 independent groups. The z test
was used for comparisons of area under the receiver operating
characteristic (AUROC) between 2 groups.41 P values <.05
were considered statistically signiﬁcant.
All authors had access to the study data and reviewed and
approved the ﬁnal manuscript.CL
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Patient Characteristics
In this cross-sectional study, there were 10 control sub-
jects and a total of 142 patients with NAFLD who underwent
MRE and PDFF measurements using MRI. TE and CAP
assessment was attempted in all of the control subjects and
patients, but 15 of these examinations failed because of
unreliable LSM and CAP (no successful acquisitions,
Supplementary Table 1). Table 1 details the principal features
and laboratory characteristics of the enrolled subjects. His-
tologic characteristics are also summarized in Table 1.
Assessment of Liver Fibrosis in Patients With
Nonalcoholic Fatty Liver Disease Using Clinical
Scoring Systems, Transient Elastography, and
Magnetic Resonance Elastography
The LSM was measured using MRE and TE in patients with
NAFLD to assess the stage of liver ﬁbrosis. The mean LSM
values (shear modulus-based) for MRE (n ¼ 142) were 2.11,
2.16, 2.62, 4.28, 5.24, and 7.93 kPa for the controls and stages
0, 1, 2, 3, and 4, respectively. The mean LSM values (Young’s
modulus-based) for TE (n ¼ 127), in patients where it was
measured successfully, were 5.32, 5.50, 7.61, 9.42, 14.70, and
24.23 kPa for the controls and stages 0, 1, 2, 3, and 4,
respectively, as shown in Figure 1A and B. The results of these
analyses revealed stepwise increases in the LSM obtained
using MRE or TE with increasing histologic severity of hepatic
ﬁbrosis (P< .001 using the Kruskal-Wallis test). To investigate
the diagnostic accuracy of the LSM obtained using MRE or TE
for liver ﬁbrosis, we calculated the AUROC curve and potential
cutoff values for the diagnosis of liver ﬁbrosis in NAFLD pa-
tients. The ROC curves for differentiating between liver
ﬁbrosis stage 0 and stages 14, 01 and 24, 02 and 34,
and 03 and 4 based on the LSM measured using MRE or TE
in NAFLD patients are shown in Figure 1B. The AUROC curve
in diagnosing liver ﬁbrosis stage 1, 2, 3, and 4 using
MRE or TE were 0.80 (95% conﬁdence interval [CI]:
0.710.90) or 0.78 (95% CI: 0.700.87), 0.89 (95% CI:
0.850.94) or 0.82 (95% CI: 0.740.90), 0.89 (95% CI:
0.830.95) or 0.88 (95% CI: 0.790.97), and 0.97 (95% CI:
0.941.00) or 0.92 (95% CI: 0.860.98), respectively. The
cutoff level and the sensitivity, speciﬁcity, positive predictive
632 Imajo et al Gastroenterology Vol. 150, No. 3
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stage are detailed in Table 2. The results indicate that MRE
had high diagnostic accuracy in the assessment of liver ﬁbrosis
compared with TE. In Table 3, data present direct compari-
sons regarding the diagnostic accuracy of noninvasive
markers, including LSM and scoring systems (such as the
Fibrosis-4 index, NAFLD ﬁbrosis score, aspartate aminotrans-
ferase to platelet ratio index, aspartate aminotransferase to
alanine transaminase ratio, and BARD score) in detecting liver
ﬁbrosis in patients with NAFLD (n ¼ 127), in which both MRE
and TE could be performed successfully. There were signiﬁ-
cantly greater diagnostic accuracy for liver ﬁbrosis stage 2
and 4 in MRE than that in TE (stage 2, MRE: AUROC ¼
0.91; 95% CI: 0.860.96 vs TE: AUROC ¼ 0.82; 95% CI:
0.740.89; P ¼ .001; stage 4 or higher, MRE: AUROC ¼ 0.97;
95% CI: 0.941.00 vs TE: AUROC: 0.92; 95% CI: 0.860.98;
P ¼ .049). The AUROC curve results indicate that MRE had
high diagnostic accuracy in the assessment of each liver
ﬁbrosis stage relative to TE and all clinical scoring systems,
and was signiﬁcantly superior to TE and the clinical scoring
systems in the diagnosis of the ﬁbrosis stage (Table 3).
Assessment of Steatosis in Patients With
Nonalcoholic Fatty Liver Disease Using Magnetic
Resonance ImagingBased Proton Density Fat
Fraction and Transient ElastographyBased
Controlled Attenuation Parameter Methods
PDFF measurements obtained using MRI, and CAP-based
measurements obtained using TE, were compared with the
steatosis grade obtained by liver biopsy. The mean PDFF
measurementswere 3.2% for control subjects (grade 0), 8.1%
for grade 1, 16.3% for grade 2, and 22.9% for grade 3
(Figure 2A). In contrast, the CAP value was 210.7 dB/m for
control subjects (grade 0), 262.9 dB/m for grade 1, 289.6 dB/
m for grade 2, and 304.9 dB/m for grade 3 (Figure 2A). ROC
curves for the PDFF (n¼ 142) and CAP (n¼ 127), in patients
where itwas successfullymeasured,were plotted for steatosis
grade, including the control subjects. For the detection of
grade1, the AUROC curve for PDFF and CAP was 0.98 (95%
CI: 0.961.00) and 0.88 (95% CI: 0.800.95), respectively,
using ROC analysis (see grade 1 in Figure 2B). Next, for the
detection of grade2 as comparedwith grade1, the AUROC
curve for the PDFF and CAP was 0.90 (95% CI: 0.810.98)
and 0.73 (95% CI: 0.640.81), respectively (see grade 2 in
Figure 2B). Finally, for the detection of grade3 as compared
with grade 2, the AUROC curve for the PDFF and CAP was
0.79 (95% CI: 0.640.95) and 0.70 (95% CI: 0.580.83),
respectively (see grade 3 in Figure 2B). The sensitivity,
speciﬁcity, positive predictive value, and negative predictive
value in the diagnosis of steatosis grade in NAFLD were
calculated based on the ROC analyses (Figure 2B).=
Figure 3. Correlation between the LSM obtained using MRE o
CAP methods and histologic parameters in control subjects a
between LSM and the grade of hepatic inﬂammatory activity
patients with NAFLD. The vertical axis represents the LSM in kP
the horizontal axis represents each grade of steatosis, inﬂamm
lation between PDFF and liver ﬁbrosis stage in patients with NAAdditionally, the diagnostic accuracy of PDFF and CAP in
detecting steatosis in patients with NAFLD (n¼ 127) in which
both PDFF and CAP could be performed successfully, are
directly compared in Table 4. There were signiﬁcantly greater
diagnostic accuracy for steatosis grade PDFF than that in CAP
(grade1 PDFF:, AUROC¼ 0.96; 95% CI: 0.921.00; vs CAP:
AUROC ¼ 0.88; 95% CI: 0.800.95; P ¼ .048. Grade 2 or
higher PDFF: AUROC ¼ 0.90; 95% CI: 0.820.97 vs CAP:
AUROC ¼ 0.73; 95% CI: 0.640.81; P < .001; grade 3 or
higher PDFF: AUROC ¼ 0.79; 95% CI: 0.650.94 vs CAP:
AUROC ¼ 0.70; 95% CI: 0.580.83; P ¼ .015). The AUROC
curve results indicate that PDFF was signiﬁcantly superior to
CAP in the diagnosis of each steatosis grade.Correlation Between Liver Stiffness
Measurements Based on Magnetic
Resonance Elastography or Transient
Elastography, and Steatosis Measurements
Based on Proton Density Fat Fraction
or Controlled Attenuation Parameter
and Histologic Parameters
We investigated the relationship between degree of
steatosis, hepatic inﬂammatory activity, or ballooned hepa-
tocytes and LSM obtained using MRE or TE, and between
the degrees of liver ﬁbrosis, hepatic inﬂammatory activity,
or ballooned hepatocytes and PDFF and CAP-based steatosis
measurements in NAFLD patients. There was a signiﬁcant
correlation between LSM and grade of hepatic inﬂammatory
activity and ballooned hepatocytes in both MRE and TE
(Figure 3A), and between PDFF and the stage of liver-only
ﬁbrosis, but not with the CAP-based measurements
(Figure 3B).Multiple Regression Analysis of Histologic
Parameters Associated With Liver Stiffness
Measurement Based on Magnetic Resonance
Elastography or Transient Elastography, and
Steatosis Measurements Based on Proton
Density Fat Fraction or Controlled
Attenuation Parameter
Next, the relationship between histologic parameters and
LSM obtained using MRE or TE, and PDFF or CAP measure-
ments was studied using multivariate regression analysis
(Supplementary Table 2). Only liver ﬁbrosis stage was
signiﬁcantly correlated with LSM using multiple regression
analysis. In addition, liver ﬁbrosis stage and steatosis grade
or only steatosis grade were correlated signiﬁcantly with the
MRI-based PDFF measurements or TE-based CAP measure-
ments using multiple regression analysis.r TE, and steatosis measurements obtained using PDFF and
nd patients with NAFLD. There was a signiﬁcant correlation
and ballooning degeneration regarding both MRE and TE in
a (shear modulus for MRE and Young’s modulus for TE) and
ation and ballooned hepatocyte. There was signiﬁcant corre-
FLD, but not CAP.
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LIVERAssessment of Nonalcoholic Steatohepatitis or
Nonalcoholic Fatty Liver Disease Activity Score
5 in Patients With Nonalcoholic Fatty Liver
Disease Using Magnetic Resonance Imaging and
Transient Elastography Methods With Serum
Keratin 18 and Alanine Transaminase Levels
We assessed the diagnostic ability of the LSM obtained
using MRE combined with MRI-based PDFF (MREþPDFF)
and the LSM obtained using TE including CAP (TEþCAP)
regarding NASH and Nonalcoholic Fatty Liver Disease
Activity Score (NAS) 5. We report the results in the
Supplementary Material. The AUROC curve results indicate
that MREþPDFF was signiﬁcantly superior to TEþCAP in
the diagnosis of NAS 5 (Supplementary Table 3;
MREþPDFF: AUROC ¼ 0.77; 95% CI: 0.670.87 vs TEþCAP:
AUROC ¼ 0.65; 95% CI: 0.540.77; P ¼ .045.). Additionally,
we assessed the diagnostic ability of MREþPDFF or TEþ
CAP with serum keratin 18 or alanine transaminase levels
concerning NASH and NAS 5. We report the results in the
Supplementary Material. We found that the addition of
serum keratin 18 and alanine transaminase levels did not
improve the diagnostic ability of MREþPDFF and TEþCAP
signiﬁcantly concerning NASH and NAS 5 (Supplementary
Figure 1 and Supplementary Tables 4–6).
Discussion
This cross-sectional study demonstrated a signiﬁcant
positive correlation between the LSM obtained using MRE
and the severity of liver ﬁbrosis in patients with NAFLD.
In addition, the diagnostic accuracy of MRE for liver
ﬁbrosis was found to be higher than that of clinical
scoring systems and TE. Although a steady stepwise in-
crease in PDFF and CAP was observed with increasing
severity of hepatic steatosis, the diagnostic accuracy of
PDFF regarding hepatic steatosis grade was also signiﬁ-
cantly superior to that of CAP. To our knowledge, this is
the ﬁrst study that provides a head-to-head comparison of
LSM measured using TE and MRE, fat accumulation eval-
uated using CAP measured by means of TE, and PDFF
measured using MRI for liver ﬁbrosis and steatosis in
biopsy-proven NAFLD.
NAFLD, which can progress to cirrhosis and hepatocel-
lular carcinoma, is considered to be the most common form
of chronic liver disease in obese patients. However, because
effective therapies for NAFLD have not yet been established,
the identiﬁcation of risk factors for hepatocellular carci-
noma, such as liver ﬁbrosis, would help to guide the
implementation of risk-reduction strategies for these
patients.42 Liver biopsy has been considered the reference
standard in the assessment of liver ﬁbrosis and steatosis,
although its limitations are well recognized and include risk
of complications and costs. In addition, the accuracy of the
procedure used to assess the severity of liver ﬁbrosis and
steatosis is questionable because of intra- and inter-observer
variation.43,44 Sampling error has also been reported, even in
patients with NASH.9 Additionally, because NAFLD occurs in
25% of all adults in many countries, it is impossible to
perform liver biopsy in all NAFLD patients. Therefore,alternatives to liver biopsy have been investigated, such as
clinical scoring systems, TE, and MRI, which can be used
repeatedly because of high safety. Although several scoring
systems for the diagnosis for liver ﬁbrosis in patients with
NAFLD have been reported previously, the Fibrosis-4 index
and NAFLD ﬁbrosis score exhibited good performance
characteristics in assessing ﬁbrosis.37,38 However, these
scoring systems have limitations, and the positive predictive
value is very low. Previous studies have indicated that TE
can be used to measure the severity of liver ﬁbrosis in
patients with NAFLD.11–13 Although TE is very useful in
diagnosing the severity of liver ﬁbrosis in NASH, its success
rate is dependent on operator expertise, as well as on other
factors (age, width of the intercostal space, ascites, BMI, and
visceral fat); Sporea et al45 have reported a rate of reliable
measurements of 81.6%, which is in line with that of Castéra
et al.46 This failure was independently associated with a BMI
>28 kg/m2 because of the low-frequency vibrations induced
by the probe.18 Other authors have suggested that a high
BMI or large amount of ascites cause the failure of TE.47–49
Indeed, in our study, TE was unsuccessful in assessing
LSM and CAP in 15 patients (about 10% of the total cohort;
Supplementary Table 1). Although a new XL probe equipped
with CAP, which became available from May 2015, has been
reported to reduce scan failure and enhance the reliability of
the measurement of ﬁbrosis and steatosis in morbidly obese
patients (BMI >28 kg/m2),47,49 the probe cannot be used in
many countries, including Japan. In addition, the diagnostic
ability of the XL probe seems to be similar to that of
the M-probe in patients who are not morbidly obese
(BMI 28 kg/m2). In contrast, because MRE uses compres-
sional and continuous waves, the elastic waves generated by
the vibrator could be effective in patients with ascites or
obesity, including patients with a BMI >28 kg/m2.50 Addi-
tionally, MRE offers more advantages than TE as follows:
First, the 2-dimensional displacement vector is assessed in
MRE, whereas only 1 directional measurement is performed
in TE, which might be vulnerable to complex waves,
including reﬂection and refraction.35 Second, the area
measured in the liver is larger in MRE than in TE, which can
avoid the sampling variability caused by the heterogeneity of
advanced ﬁbrosis.51,52 In fact, in our study, 9 (7.1%) patients
with advanced ﬁbrosis (stage 34) were diagnosed by TE as
“mild ﬁbrosis” out of 127 patients with NAFLD. In contrast,
only 4 (2.8%) patients with advanced ﬁbrosis were diag-
nosed using MRE as “mild ﬁbrosis” out of 142 patients with
NAFLD; this suggested that TE may misclassify patients with
advanced ﬁbrosis as compared with MRE. In contrast, MRE
may misclassify patients with mild ﬁbrosis (stage 02)
relative to TE. Indeed, 12 (7.1%) patients with mild ﬁbrosis
were diagnosed using TE as having advanced ﬁbrosis out of
127 patients with NAFLD. In contrast, 22 (15.5%) patients
with mild ﬁbrosis were diagnosed using MRE as having
advanced ﬁbrosis out of 142 patients with NAFLD. We
consider that this misclassiﬁcation using MRE was associ-
ated with sampling errors involved in the use of liver biopsy
and TE.
Hepatic fat accumulation is receiving increasing atten-
tion in clinical practice because the prevalence of steatosis
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Rassociated with obesity is dramatically affecting developed
countries.53,54 In addition, it is also important for liver
transplantation because a 30% fat content contraindi-
cates liver donation.55 Consequently, the establishment of
new noninvasive approaches is essential in accurately
determining the hepatic fat concentration, and in facili-
tating the correct diagnosis and monitoring of steatosis. To
date, there have been no speciﬁc biochemical or serologic
tests that are able to diagnose the presence of steatosis, or
to quantitate the degree of steatosis. In our study, PDFF
and CAP each correlated reasonably well with biopsy-
proven steatosis, and signiﬁcantly differentiated controls
from NAFLD patients with steatosis grades of 1, 2, and 3.
However, the diagnostic accuracy of MRI-based PDFF for
each steatosis grade was superior to TE-based CAP in the
control subjects and patients with NAFLD, in particular in
the case of advanced steatosis (grades 23). Although MRE
and PDFF seem to be superior to TE including CAP in the
diagnosis of ﬁbrosis and steatosis in patients with NAFLD,
costs associated with the use of MRI are higher than those
for TE (Supplementary Table 7). However, MRI can be used
to scan the whole liver for screening with the objective of
detecting hepatocellular carcinoma at the same time as
measuring the LSM and PDFF. Therefore, considered
overall, the cost beneﬁt of MRI seems to be comparable
with TE.
Our study had several limitations. First, the use of liver
biopsy as the gold standard for assessing liver pathology has
limitations associated with sampling errors, as well as intra-
and inter-observer variability, which are at least partly
linked to the size of the biopsy. Second, we did not consider
the dynamic effect of hepatic perfusion in our study, which
could cause elevated LSM unrelated to the liver disease
itself. This effect has been observed in TE and MRE
studies.56,57 Third, the drawing of ROIs on the MRE image is
not yet fully standardized. We measured the mean of 3 ROIs
to decrease measurement bias in this study. Finally, patient
selection bias may also have been the result of liver biopsies
being more likely to be performed on NAFLD patients at risk
for NASH with advanced ﬁbrosis.
In conclusion, this is the ﬁrst study that has demon-
strated that MRI-based MRE and PDFF methods have
higher diagnostic accuracy in detecting liver ﬁbrosis and
steatosis, respectively, in patients with NAFLD, relative to
the TE-based LSM and CAP methods. This was conﬁrmed
by the liver biopsy results, which remains the gold stan-
dard for the evaluation of the severity of liver ﬁbrosis and
steatosis. Further studies must be conducted to explore the
prognostic value of the results of these diagnostic tech-
niques to determine the long-term outcomes of patients
with NAFLD.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Methods
Histopathologic and Immunohistochemical
Evaluations
One of the 2 pathologists was a hepatopathologist.
Steatosis affecting <5%, 5%33%, 33%66%, and >66%
of hepatocytes was classiﬁed as grades 0, 1, 2, and 3,
respectively. Lobular inﬂammation was graded according to
the number of inﬂammatory foci per ﬁeld of view (FOV) at a
magniﬁcation of 200, with 0, <2, 24, and >4 foci per
ﬁeld classiﬁed as grades 0, 1, 2 and 3, respectively. Hepa-
tocellular ballooning involving no, few, and many cells was
classiﬁed as grades 0, 1, and 2, respectively.
Magnetic Resonance Elastography
Continuous longitudinal mechanical waves (60 Hz) were
generated using a passive acoustic driver placed against the
anterior chest wall. A 2-dimensional spin-echo planar MRE
sequence was used to acquire axial wave images with the
following parameters: repetition time/echo time: 50/23 ms;
continuous sinusoidal vibration: 60 Hz; FOV: 3242 cm;
matrix size: 256  64; ﬂip angle: 30 degrees; section
thickness: 10 mm; 4 evenly spaced phase offsets; and 4
pairs of 60-Hz trapezoidal motion encoding gradients with
zeroth and ﬁrst moment nulling along the through-plane
direction. All processing steps were applied automatically,
without manual intervention, to yield quantitative images of
tissue shear stiffness in kilopascals. On each section of the
MR magnitude image from the MRE acquisition, the ROIs
were drawn to include only the parenchyma of the liver,
avoiding the edges of the liver and large blood vessels. The
ROIs also excluded regions where the phase signal-to-noise
ratio (the ratio of wave amplitude to the noise in the wave
images) was <5.
Assessment of Steatosis Using Magnetic
Resonance ImagingBased Proton
Density Fat Fraction
A fast gradient echo sequence was performed to ac-
quire in-phase and out-of-phase images with the following
parameters: repetition time/echo times: 110/2.1 ms; 4.3;
ﬂip angle: 70 degree; matrix: 256  192; axial imaging
plane; section thickness: 6 mm; FOV: 3444 cm; frac-
tional phase FOV: 0.751; one signal acquired; band-
width, 62.5 kHz; imaging time, 2 breath holds (about 16
seconds each).
Transient Elastography
TE was performed in control subjects and NAFLD pa-
tients under fasting conditions for 12 hours. This system is
equipped with a probe and an ultrasonic transducer moun-
ted on the axis of a vibrator. A vibration of mild amplitude
and low frequency is transmitted from the vibrator to the
tissue by the transducer itself; this induces the propagation
of an elastic shear wave through the tissue. The speed of the
propagating wave is estimated using a 1-dimensional ultra-
sound technique, and this is automatically converted to a
measurement in terms of Young’s modulus in units of kilo-
pascals. TE-based measurements of Young’s modulus can be
compared approximately to MRE-based measurements of
shear modulus by dividing the TE measurements by a factor
of 3. In this study, only TEmeasurement with at least 10 valid
shots and a success rate of 60% were considered reliable,
and were used for statistical analysis.
Scoring Systems
The values for the upper limit of normal were set ac-
cording to the International Federation of Clinical Chemis-
try: an aspartate aminotransferase level of 35 U/L for men
and 30 U/L for women (these levels were comparable with
those used in other analyses).
Keratin 18 fragments
Serum samples used in the current study were aliquots
(0.5 mL) from the original samples in which blood from
fasting subjects was collected into serum separator tubes,
allowed to clot for at least 30 minutes at room temperature,
and centrifuged at 1800g for 15 minutes. Aliquots of serum
were immediately frozen. Processing was completed within
2 hours, and samples were free of hemolysis.
The serum caspase-cleaved K18 fragment (K18 [caspase-
cleaved cytokeratin-18]) levels were determined using the
M30-Apoptosense enzyme-linked immunosorbent assay
(Peviva AB, Bromma, Sweden). Working range and detection
limit of the assay kit is 751000 U/L and 20 U/L. The
standard curve and K18 values were determined using the
Soft-max Pro software accompanying the microplate reader.
Results
Assessment of Nonalcoholic Steatohepatitis or
Nonalcoholic Fatty Liver Disease Activity Score
5 in Patients With Nonalcoholic Fatty Liver
Disease Using Magnetic Resonance Imaging and
Transient Elastography Methods With Serum
Keratin 18 and Alanine Transaminase Levels.
We assessed the diagnostic ability of the LSM obtained
using MRE combined with MRI-based PDFF (MREþPDFF)
and the LSM obtained using TE including CAP (TEþCAP)
regarding NASH and NAS 5. For the detection of NASH or
NAS 5, the AUROC curve for MRIþPDFF and TEþCAP was
0.81 (95% CI: 0.730.89) and 0.80 (95% CI: 0.730.88), or
0.77 (95% CI: 0.670.87), and 0.65 (95% CI: 0.540.77),
respectively, using ROC analysis (Supplementary Table 3).
Mean serum K18 levels exhibited stepwise increases
with increasing histologic severity of ballooned hepatocytes
(Supplementary Figure 1; 245 U/L (range, 141254 U/L)
for control, 388 U/L (range, 211965 U/L) for grade 0, 525
U/L (range, 793259 U/L) for grade 1, and 867U/L (range
4141721 U/L) for grade 2; P ¼ .013 using the Kruskal-
Wallis test). The AUROC curve regarding the performance
of the serum K18 levels in distinguishing the grade of
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ballooned hepatocyte is shown in Supplementary Table 4.
Additionally, the cutoff level and the sensitivity, speciﬁcity,
positive predictive value, and negative predictive value for
each ballooned hepatocyte grade are also detailed in
Supplementary Table 4.
Finally,weanalyzed thediagnostic abilityof serumK18and
alanine transaminase (ALT) levels with MREþPDFF and
TEþCAP in relation to NASH and NAS 5. The AUROC curve
results indicate thatMREþPDFFþK18orALTwas signiﬁcantly
superior to TEþCAPþK18 or ALT in the diagnosis of NAS 5
(Supplementary Tables 5 and 6). However, we found that the
addition of serum K18 or ALT levels did not improve the
diagnostic ability of MREþPDFF and TEþCAP signiﬁcantly
concerningNASHandNAS5 (SupplementaryTables5and6).
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Supplementary Figure 1. Relationship between serum K18
levels and ballooned hepatocyte grade in patients with
NAFLD. (A) A steady stepwise increase in serum K18 levels
was observed with increasing severity of ballooned hepato-
cytes (Kruskal-Wallis test; P ¼ .013). The vertical axis repre-
sents serum K18 levels in U/L and the horizontal axis
represents each ballooned hepatocyte grade. The graph
represents the interquartile range (box), median (dot), and
range (lines) of the serum K18 levels.
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Supplementary Table 1.The Cases in Which it Was Not
Possible to Measure LSM and CAP
Using TE
Case
(n ¼ 15)
BMI
(kg/m2) Ascites
Interposition of
intestine or colon
1 29.4 -
2 31.1 - -
3 28.5 - -
4 29.4 - -
5 32.2 - -
6 33.2 - -
7 27.8 - -
8 30.2 - -
9 28.9 - -
10 29.3 - -
11 27.0 þ -
12 26.5 þ -
13 27.2 þ -
14 25.9 - þ
15 26.2 - þ
Supplementary Table 2.Multiple Regression Analysis of
Histologic Parameters Associated
With Increased LSM for MRE or TE
and Increased Fat Accumulation for
PDFF for MRI or CAP for TE
Case
(n ¼ 15)
BMI
(kg/m2) Ascites
Interposition of
intestine or colon
1 29.4 -
2 31.1 - -
3 28.5 - -
4 29.4 - -
5 32.2 - -
6 33.2 - -
7 27.8 - -
8 30.2 - -
9 28.9 - -
10 29.3 - -
11 27.0 þ -
12 26.5 þ -
13 27.2 þ -
14 25.9 - þ
15 26.2 - þ
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Supplementary Table 3.Diagnostic Accuracy of MRE Combined with MRI-Based PDFF and TE Combined TE-Based CAP in
Detecting NASH and NAS >5
MREþPDFF (n ¼ 127) TEþCAP (n ¼ 127)
AUROC 95%CI AUROC 95%CI
vs MREþPDFF
P value
NASH 0.81 0.73–0.89 0.80 0.73–0.88 0.475
NAS  5 0.77 0.67–0.87 0.65 0.54–0.77 0.045a
aMREþPDFF was signiﬁcantly superior to TEþCAP.
Supplementary Table 4.Diagnostic Accuracy of Serum K18 Levels in Detecting Each Grade of Ballooned Hepatocyte
Ballooned hepatocyte grade
K18 (n ¼ 127)
Cut off level (U/L) AUROC 95%CI Se Sp PPV NPV
 1 354 0.67 0.53–0.81 64.4 68.9 86.2 39.2
 2 414 0.80 0.67–0.92 100.0 54.7 17.2 100.0
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Supplementary Table 5.Diagnostic Accuracy of MREþPDFF or TEþCAP Combined With Serum K18 Levels Determined by
Detecting NASH and NAS >5
Parameters
MREþPDFFþK18 (n ¼ 127) TEþCAPþK18 (n ¼ 127)
AUROC 95% CI P value
P value
(MREþPDFF vs
MREþPDFFþK18) AUROC 95% CI P value
P value
(TEþCAP vs
TEþCAPþK18)
P value
(MREþPDFFþK18 vs
TEþCAPþK18)
NASH 0.82 0.73–0.92 <.001 0.543 0.82 0.75–0.89 <.001 0.539 0.668
NAS  5 0.78 0.68–0.88 .002 0.717 0.66 0.54–0.78 .048 0.684 0.049a
aMREþPDFFþK18 was signiﬁcantly superior to TEþCAPþK18.
Supplementary Table 6.Diagnostic Accuracy of MREþPDFF or TEþCAP Combined With Serum ALT Levels Determined by
Detecting NASH and NAS >5
Parameters
MREþPDFFþALT (n ¼ 127) TEþCAPþALT (n ¼ 127)
AUROC 95% CI P value
P value
(MREþPDFF vs
MREþPDFFþALT) AUROC 95% CI P value
P value
(TEþCAP vs
TEþCAPþALT)
P value
(MREþPDFFþALT vs
TEþCAPþALT)
NASH 0.82 0.74–0.91 <.001 0.485 0.80 0.72–0.88 <.001 0.515 0.325
NAS  5 0.77 0.67–0.87 .004 0.722 0.67 0.56–0.78 .043 0.483 0.047a
aMREþPDFFþALT was signiﬁcantly superior to TEþCAPþALT.
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Supplementary Table 7.The Cost of MRI and TE Method in
Several Countries
Countries
Cost (US dollars)
MRE TE
Japan 130 65
USA 2871 137
United Kingdom 335 216
France 363 29
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